SCHEMBL7814583

SCHEMBL7814583

Cc1ccc(CC(C)CC(=O)O)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
FFAR1 O14842 2/20 0.46
ITGB3 P05106 1/20 0.44
ITGB1 P05556 1/20 0.44
ITGAV P06756 1/20 0.44
ITGB5 P18084 1/20 0.44
ITGB6 P18564 1/20 0.44
ACACB O00763 1/20 0.44
CPA1 P15085 2/20 0.43
PPARG P37231 1/20 0.43
PPARA Q07869 1/20 0.43
CPB1 P15086 1/20 0.43
CPA3 P15088 1/20 0.43
CPB2 Q96IY4 1/20 0.43
HPGD P15428 1/20 0.42
LMNA P02545 1/20 0.42
ALB P02768 1/20 0.42
ESR1 P03372 1/20 0.42
ALOX5 P09917 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6176371 0.85 TAAR1 (0.52) ITGB3ITGB1ITGAVITGB5ITGB6
SCHEMBL14032253 0.85 TAAR1 (0.52) ITGB3ITGB1ITGAVITGB5ITGB6
SCHEMBL24897744 0.85 ALDH1A1 (0.48) ITGB3ITGB1ITGAVITGB5ITGB6
SCHEMBL14542152 0.84 CPA1 (0.60) ITGB3ITGB1ITGAVITGB5ITGB6
SCHEMBL750878 0.84 CPA1 (0.60) ITGB3ITGB1ITGAVITGB5ITGB6
SCHEMBL16488807 0.84 CPA1 (0.60) ITGB3ITGB1ITGAVITGB5ITGB6
SCHEMBL3512373 0.83 MEN1 (0.51) KMT2AMEN1ACACBPPARGPPARA
SCHEMBL15134800 0.83 NPC1 (0.46) ITGB3ITGB1ITGAVITGB5ITGB6
SCHEMBL21427056 0.83 EPHX1 (0.43) ACACBPPARGPPARAHPGDALOX5
SCHEMBL763623 0.83 MME (0.49) KMT2AMEN1ITGB3ITGB1ITGAV

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11702427-B2 Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2023-07-18 US disclosed
US-20230173093-A1 CHARGE VARIANT LINKERS SEAGEN INC (US) 2023-06-08 US disclosed
US-9138493-B2 Radioiodinated fatty acids GE HEALTHCARE LIMITED (GB) 2015-09-22 US disclosed
US-20130272960-A1 RADIOIODINATED FATTY ACIDS GE HEALTHCARE LIMITED (GB) 2013-10-17 US disclosed
EP-1091958-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2001-04-18 EP disclosed
WO-2000001692-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2000-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130272960-A1 RADIOIODINATED FATTY ACIDS FFAR3, FFAR1, FFAR2 KMT2A 3313/4885MEN1 1752/4885FFAR1 2/4885
US-11702427-B2 Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same HAVCR2, HPD, CYP24A1 KMT2A 1259/4885MEN1 1785/4885FFAR1 3709/4885
US-20230173093-A1 CHARGE VARIANT LINKERS SSB, UACA, CDA KMT2A 199/4885MEN1 515/4885FFAR1 4086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.